• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

偏远和农村苏格兰地区医生对使用直接口服抗凝剂治疗非瓣膜性心房颤动的看法和经验:一项调查。

Prescribers' views and experiences of using direct acting oral anticoagulants in the management of nonvalvular atrial fibrillation: A survey in remote and rural Scotland.

机构信息

School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen, UK.

Department of Medicine, Raigmore Hospital, Inverness, UK.

出版信息

Br J Clin Pharmacol. 2019 Oct;85(10):2414-2422. doi: 10.1111/bcp.14069. Epub 2019 Aug 2.

DOI:10.1111/bcp.14069
PMID:31313317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6783578/
Abstract

AIMS

A recent systematic review highlighted the lack of robust studies on prescribers' perspectives of direct-acting oral anticoagulants (DOACs) for nonvalvular atrial fibrillation. The aim was to determine prescribers' views and experiences of prescribing DOACs.

METHODS

A cross-sectional survey of prescribers in a remote and rural area of Scotland. Survey items were: demographics; prescribing of DOACs; views of potential influences on DOAC prescribing; knowledge of prescribing guidelines; and experiences. Items on potential influences were based on the Theoretical Domains Framework. Data were analysed using descriptive and inferential statistics, and content analysis of responses to open questions. Principal component analysis was performed on the items of potential influences.

RESULTS

In total, 154 responses were received, 120 (77.9%) from doctors, 18 (11.7%) from nurse prescribers and 10 (6.4%) from pharmacist prescribers (6 missing). Principal component analysis of the Theoretical Domains Framework items of potential influences gave 4 components. Component scores for (i) role of professionals, their knowledge and skills and (ii) influences on prescribing were positive. Those for (iii) consequences of prescribing and (iv) monitoring for safety and effectiveness were more neutral. There were low levels of agreement for statements relating to DOACs being more effective, safer and cost-effective than warfarin. There were similar responses around the complexity of bleeding management and detection of over and under-anticoagulation.

CONCLUSION

This study has identified several key issues of DOAC prescribing (e.g. bleeding management) hence further emphasis is required in continuing professional development and during guideline implementation and evaluation.

摘要

目的

最近的一项系统评价强调了缺乏关于直接作用的口服抗凝剂(DOACs)用于非瓣膜性心房颤动的处方医生观点的稳健研究。目的是确定处方医生对开具 DOAC 的看法和经验。

方法

对苏格兰偏远农村地区的处方医生进行横断面调查。调查项目包括:人口统计学信息;DOAC 的开具情况;对可能影响 DOAC 开具的因素的看法;对开具指南的了解程度;以及经验。潜在影响因素的项目基于理论领域框架。使用描述性和推断性统计以及对开放性问题的内容分析来分析数据。对潜在影响因素的项目进行主成分分析。

结果

共收到 154 份回复,其中 120 份(77.9%)来自医生,18 份(11.7%)来自护士处方者,10 份(6.4%)来自药剂师处方者(6 份缺失)。潜在影响因素的理论领域框架项目的主成分分析给出了 4 个组成部分。专业人员角色、他们的知识和技能以及(ii)对处方的影响的组成部分得分是积极的。(iii)处方的后果和(iv)监测安全性和有效性的组成部分得分则更为中性。与 DOAC 比华法林更有效、更安全和更具成本效益的说法存在低水平的一致性。关于出血管理和检测过度和不足抗凝的复杂性,也存在类似的反应。

结论

本研究确定了 DOAC 开具处方的几个关键问题(例如出血管理),因此需要在继续专业发展以及在指南实施和评估过程中进一步强调。

相似文献

1
Prescribers' views and experiences of using direct acting oral anticoagulants in the management of nonvalvular atrial fibrillation: A survey in remote and rural Scotland.偏远和农村苏格兰地区医生对使用直接口服抗凝剂治疗非瓣膜性心房颤动的看法和经验:一项调查。
Br J Clin Pharmacol. 2019 Oct;85(10):2414-2422. doi: 10.1111/bcp.14069. Epub 2019 Aug 2.
2
Prescribers' perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation.处方医生对非瓣膜性心房颤动中直接口服抗凝剂的益处和局限性的看法。
Pharm Pract (Granada). 2020 Apr-Jun;18(2):1936. doi: 10.18549/PharmPract.2020.2.1936. Epub 2020 Jun 13.
3
Anticoagulant Prescribing for Non-Valvular Atrial Fibrillation in the Veterans Health Administration.退伍军人事务部非瓣膜性心房颤动的抗凝药物处方。
J Am Heart Assoc. 2019 Sep 3;8(17):e012646. doi: 10.1161/JAHA.119.012646. Epub 2019 Aug 23.
4
Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.直接口服抗凝剂和华法林治疗心房颤动患者的处方模式和结局:真实世界分析。
J Cardiovasc Pharmacol Ther. 2019 Sep;24(5):428-434. doi: 10.1177/1074248419841634. Epub 2019 Apr 29.
5
Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries.美国医疗保险受益人群中临床医生开具直接口服抗凝药物的趋势。
JAMA Netw Open. 2021 Dec 1;4(12):e2137288. doi: 10.1001/jamanetworkopen.2021.37288.
6
Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.直接口服抗凝剂与华法林在非瓣膜性心房颤动中的围手术期结局。
Circulation. 2018 Oct 2;138(14):1402-1411. doi: 10.1161/CIRCULATIONAHA.117.031457.
7
The Tasmanian atrial fibrillation study: Transition to direct oral anticoagulants 2011-2015.塔斯马尼亚心房颤动研究:2011 - 2015年向直接口服抗凝剂的转变
Cardiovasc Ther. 2017 Jun;35(3). doi: 10.1111/1755-5922.12254.
8
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.口服 Xa 因子抑制剂与华法林在有跌倒高风险的非瓣膜性心房颤动患者中的安全性和有效性。
J Thromb Thrombolysis. 2019 Oct;48(3):366-372. doi: 10.1007/s11239-019-01898-7.
9
Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?心房颤动中口服抗凝剂的使用欠佳:直接口服抗凝剂的引入是否改善了处方实践?
Am J Cardiovasc Drugs. 2016 Jun;16(3):183-200. doi: 10.1007/s40256-016-0161-8.
10
Pharmacist Use of a Population Management Dashboard for Safe Anticoagulant Prescribing: Evaluation of a Nationwide Implementation Effort.药剂师使用人群管理仪表板进行安全抗凝药物处方:全国实施努力的评估。
J Am Heart Assoc. 2024 Sep 17;13(18):e035859. doi: 10.1161/JAHA.124.035859. Epub 2024 Sep 9.

引用本文的文献

1
[Prescribing behavior of Bavarian general practitioners at the inpatient-outpatient interface within the context of the Bavarian active substance agreement-qualitative results of the WirtMed Study].[巴伐利亚活跃物质协议背景下巴伐利亚全科医生在住院-门诊衔接处的处方行为——WirtMed研究的定性结果]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Sep;65(9):900-908. doi: 10.1007/s00103-022-03563-6. Epub 2022 Jul 15.
2
Prescribers' perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation.处方医生对非瓣膜性心房颤动中直接口服抗凝剂的益处和局限性的看法。
Pharm Pract (Granada). 2020 Apr-Jun;18(2):1936. doi: 10.18549/PharmPract.2020.2.1936. Epub 2020 Jun 13.

本文引用的文献

1
A systematic review of clinicians' views and experiences of direct-acting oral anticoagulants in the management of nonvalvular atrial fibrillation.系统评价临床医生对直接口服抗凝剂在非瓣膜性心房颤动管理中的观点和经验。
Br J Clin Pharmacol. 2018 Dec;84(12):2692-2703. doi: 10.1111/bcp.13739. Epub 2018 Sep 22.
2
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.2018 年欧洲心脏病学会关于非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中应用的实用指南。
Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
3
What Influences the Cost Effectiveness of Dabigatran versus Warfarin for Stroke Prevention in Atrial Fibrillation: A Systematic Review.达比加群与华法林预防心房颤动患者卒中的成本效益受哪些因素影响:一项系统评价
J Popul Ther Clin Pharmacol. 2017 May 2;24(2):e1-e20. doi: 10.22374/1710-6222.24.2.1.
4
Trends in the prescription of novel oral anticoagulants in UK primary care.英国初级保健中新型口服抗凝剂的处方趋势。
Br J Clin Pharmacol. 2017 Sep;83(9):2096-2106. doi: 10.1111/bcp.13299. Epub 2017 May 4.
5
Direct new oral anticoagulants: follow-up, guidelines and bleeding complications in general practice-a survey of Swiss general internal medicine practitioners.新型直接口服抗凝剂:全科医疗中的随访、指南及出血并发症——瑞士全科内科医生的一项调查
Springerplus. 2016 Nov 29;5(1):2030. doi: 10.1186/s40064-016-3722-z. eCollection 2016.
6
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
7
Reversal agents for direct oral anticoagulants: A focused review.直接口服抗凝剂的逆转剂:重点综述。
Int J Cardiol. 2016 Nov 15;223:244-250. doi: 10.1016/j.ijcard.2016.07.304. Epub 2016 Aug 12.
8
A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation.阿哌沙班用于非瓣膜性心房颤动卒中预防的成本效益的系统文献综述
Cardiol Ther. 2016 Dec;5(2):171-186. doi: 10.1007/s40119-016-0066-2. Epub 2016 Jul 25.
9
Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention.非瓣膜性心房颤动患者接受口服抗凝治疗预防卒中的价值观和偏好。
Can J Cardiol. 2016 Jun;32(6):747-53. doi: 10.1016/j.cjca.2015.09.023. Epub 2015 Nov 10.
10
The use of theory in research.理论在研究中的应用。
Int J Clin Pharm. 2016 Jun;38(3):615-9. doi: 10.1007/s11096-015-0216-y.